Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic rhinitis patients
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lolium perenne
peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic rhinitis patients
Authors
Keywords
-
Journal
ALLERGY
Volume 73, Issue 6, Pages 1254-1262
Publisher
Wiley
Online
2018-01-11
DOI
10.1111/all.13392
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lolium perenne peptides for treatment of grass pollen allergy: A randomized, double-blind, placebo-controlled clinical trial
- (2018) Mohamed H. Shamji et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Sublingual Immunotherapy for Allergic Rhinitis
- (2017) Linda S. Cox JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study
- (2016) François Spertini et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Conjunctival Provocation Tests: A Predictive Factor for Patients' Seasonal Allergic Rhinoconjunctivitis Symptoms
- (2015) Kristian Kruse et al. Journal of Allergy and Clinical Immunology-In Practice
- Exploratory study of tolerability and immunological effect of a short up-dosing immunotherapy phase with a standardised allergen extract derived from pollen of Olea europaea
- (2015) Carmen Moreno et al. Clinical and Translational Allergy
- Allergen immunotherapy on the way to product-based evaluation—a WAO statement
- (2015) Claus Bachert et al. World Allergy Organization Journal
- A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol
- (2014) L. Klimek et al. ALLERGY
- Negative Clinical Results from a Randomised, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy of Two Doses of Immunologically Enhanced, Grass Subcutaneous Immunotherapy Despite Dose-Dependent Immunological Response
- (2014) Jörg Kleine-Tebbe et al. CLINICAL DRUG INVESTIGATION
- Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy
- (2013) K. Aasbjerg et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Objectifying the Conjunctival Provocation Test: Photography-Based Rating and Digital Analysis
- (2013) S. Dogan et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study
- (2012) L. Klimek et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Immunologic Effect and Tolerability of Intra-Seasonal Subcutaneous Immunotherapy With an 8-Day Up-Dosing Schedule to 10,000 Standardized Quality-Units: A Double-Blind, Randomized, Placebo-Controlled Trial
- (2012) Oliver Pfaar et al. CLINICAL THERAPEUTICS
- Fel d 1–derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study
- (2012) Deepen Patel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy
- (2012) Moises A Calderon et al. Clinical and Translational Allergy
- Regulatory environment for allergen-specific immunotherapy
- (2011) S. Kaul et al. ALLERGY
- Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy
- (2011) M. H. Shamji et al. ALLERGY
- Risks and benefits of allergen immunotherapy
- (2009) Barbara Rogala et al. Expert Opinion On Drug Safety
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started